Godavari Biorefineries Limited (GBL), an ethanol producer and global pioneer in bio-based chemical manufacturing, delivered a resilient performance in Q1 FY26. Despite the seasonal nature of some business segments, the company reported steady revenue. It also saw strong momentum in its Bio-based Chemicals division.
Performance Commentary: Resilience Amid Seasonality
Samir Somaiya, Chairman and Managing Director, stated, “Q1 FY26 has been a quarter of resilience and progress for our Company. Despite the seasonality in some segments, we improved our performance, with revenue from operations rising to ₹533.2 crore and EBITDA reaching ₹6.5 crore. Notably, our Bio-based Chemicals segment recorded a 43% year-on-year growth in EBITDA.”
Ethanol Segment Rebounds with Regulatory Support
Ethanol production reached 26,057 KL, aided by the restoration of the ethanol blending program for the 2024–25 sugar season. The policy shift allowed the company to ramp up production using B-heavy molasses. Looking ahead, GBL’s upcoming grain-based ethanol capacity is expected to act as a key growth catalyst, enhancing its multi-feedstock capabilities.
Breakthroughs in Drug Discovery and Global Patents
GBL reported significant progress in its drug discovery initiatives, marking a strategic diversification into high-value innovation. A European patent for its novel anti-cancer molecule has now been validated in Spain, the United Kingdom, and as a Unitary Patent across multiple EU member states. Safety trials for this molecule have concluded successfully, with no dose-limiting toxicity (DLT) reported.
As per the press release, in a parallel development, the company secured a patent from China’s CNIPA for a second novel anti-cancer compound — HYDROXY-1,4-NAPHTHALENEDIONE. This molecule belongs to a new class of compounds showing potent in vitro activity against cancer and cancer stem cells, with promising efficacy in breast and prostate cancers.
Strategic Outlook: Strengthening Core and Innovation Pipelines
GBL continues to sharpen its focus on:
*Scaling the Bio-based Chemicals segment through ongoing debottlenecking and development of high-margin specialty chemicals
*Expanding ethanol capacity, particularly in grain-based production, to ensure feedstock flexibility
*Investing in R&D across bio-chemicals and pharmaceuticals to build a robust pipeline of innovation-driven growth
Somaiya added, “With our strategic initiatives, we are confident of delivering long-term, sustainable value to all stakeholders while reinforcing our leadership in the bio-based economy.”
